DOYLESTOWN, Pa. - Aprea Therapeutics, Inc. (NASDAQ: NASDAQ:APRE), a biopharmaceutical company with a market capitalization of $21.2 million focused on developing treatments targeting cancer cell ...
Dr. Cigler, who serves as co-principal investigator for the initiative, will work alongside Dr. Vered Stearns and a multidisciplinary team at Weill Cornell Medicine to address the unique needs of ...
Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while ...